XOMA Corporation
(NASDAQ: XOMA)
3.60
-0.24
-6.25%
-0.24
-6.25%
MORE ON XOMA
COMPANY INFORMATION
| Exchange: | NASDAQ national market |
| Stock: | XOMA Corp |
| Industry: | Biotechnology |
| Employees: | 166 |
DESCRIPTION
| XOMA Ltd. is a biopharmaceutical company, which is engaged in the discovery, development and manufacture of therapeutic antibodies and other agents designed to treat inflammatory, autoimmune, infectious and oncological diseases. The company builds a product pipeline that includes multiple proprietary and collaborative development programs. Its proprietary preclinical pipeline includes classes of antibodies that activate, sensitize, or deactivate the insulin receptor in vivo, that have been named as XMet. This portfolio of antibodies represents potential new therapeutic approaches to the treatment of diabetes and several diseases that involve insulin, which it believe may be orphan drug opportunities. Its main product candidate is XOMA 052, a potent monoclonal antibody with the potential to improve the treatment of patients with a number of diseases in which inflammation is either the cause or plays a considerable role. The company receives royalties on approved products, RAPTIVA®, which is marketed globally for the treatment of chronic moderate-to-severe plaque psoriasis, LUCENTIS®, which is marketed globally for the treatment of neovascular (wet) age-related macular degeneration, and the Company no longer receives royalties on sales of CIMZIA®. XOMA has granted more than 60 licenses to biotechnology and pharmaceutical companies to use the Company’s patented and proprietary technologies relating to bacterial expression of recombinant pharmaceutical products. |
DATA PROVIDERS
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
RECENT QUOTES
WATCHLIST
You're not signed in
You’re not signed in to MSN Money, so you’re seeing the Watchlist that is tied to your computer. For a more consistent Watchlist experience, sign in to MSN Money.
Learn more
Sponsored by:
MARKET UPDATE
[BRIEFING.COM] The major averages continue to hover near their lows with the S&P 500 off by 0.2%. Yesterday's top performer, the industrial sector, is among the early laggards today as defense companies lag. General Electric (GE 24.15, -0.18) trades
...
More
MORE MARKET NEWS
Sponsored by: